Hemab Therapeutics raises $157 million in Series C financing with continued support from Novo Holdings

• $157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors

• Financing readies Hemab for registration studies following successful advancement of sutacimig through Phase 2 in Glanzmann thrombasthenia and continued progress of HMB-002 in Von Willebrand disease

• Financing positions Hemab to continue expanding the clinical pipeline

CAMBRIDGE, MA, USA & COPENHAGEN, Denmark, Oct 27, 2025.
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round.

The round was led by Sofinnova Partners with substantial participation from a large long-only global asset management company and participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. In connection with this financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.

Advancing breakthrough treatments for Glanzmann Thrombasthenia and Factor VII deficiency
Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide. The financing follows the successful completion of sutacimig’s Phase 2 study in GT with aims to progress to the first registration study in 2026 and to expand into a Phase 2 study in Factor VII deficiency.

“As a mother of two boys with GT, I live with a constant fear, knowing from experience that a simple fall or injury can lead to a life-threatening bleed,” said Alexandra Sullivan, patient advocate and mother. “We feel so limited by the lack of effective treatments in the event of an emergency and cannot stress enough how urgently we feel the need for breakthrough treatments. Our greatest hope is to offer our children a treatment that will allow them to live normal lives. Investment in the development of modern therapies for these underserved patients brings hope to our family.”

Tackling Von Willebrand Disease treatment
The financing also supports advancing HMB-002 towards a registration study. HMB-002 is Hemab’s antibody-based treatment with Phase 1 proof of mechanism data showing that it directly targets the underlying pathophysiology of Von Willebrand disease (VWD) by increasing both Von Willebrand Factor (VWF) and Factor VIII levels. This innovative approach is designed to address the root cause of the bleeding disorder.

From inception, Hemab’s program development has been shaped by a portfolio of groundbreaking natural history studies including GT360, FVIID360 and VWD360, which have challenged historical assumptions and uncovered the overlooked burden of these diseases. Beyond severe, life-threatening bleeds, people face chronic pain, immobility, anxiety, depression and fatigue – yet only reactive or episodic treatments exist.

Expanding pipeline and building the ultimate clotting company
The additional capital enables Hemab to advance additional novel drug candidates into clinical development, with HMB-003 expected to be announced in H1 2026. This expanded pipeline reinforces Hemab’s commitment to developing comprehensive treatment solutions across the spectrum of high unmet need bleeding disorders.

“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company,” said Benny Sorensen, MD, PhD, CEO of Hemab. “We carefully listen to people living with clotting diseases and collaborate closely with people affected by these conditions and families to deliver 21st century treatment options. Hemab’s unprecedented deep domain expertise in clotting science, combined with our proven capabilities in advancing programs from early development through approval and commercialisation, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long.”

Novo Holdings’ strategic involvement from seed stage to advanced development
Novo Holdings has been closely involved with Hemab Therapeutics since its creation in 2020 through its Seed Investments team. Founded to address rare bleeding and thrombotic disorders, Novo Holdings co-led the US$55 million Series A in 2021 and participated in the US$135 million Series B in 2023, supporting the company’s clinical and organisational development.

As an active board participant, Novo Holdings has provided strategic guidance from inception to scale-up. Today, Hemab remains part of Novo Holdings’ life-science portfolio, exemplifying its commitment to building and supporting innovative biotech companies from early concept to advanced clinical stages.

“As founding and long-term investor in Hemab it has been a great pleasure to support the development of Hemab from start-up and into a successful mature development-stage company,” said Jørgen Søberg Petersen, Senior Partner, Novo Holdings. “With its patient-centric approach to R&D, Hemab is a shiny example of a biotech company that is rewriting the medical textbooks through the development of functional cures for these severe and underserved bleeding disorders.”

About Glanzmann Thrombasthenia
Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international Glanzmann’s 360 (GT360) natural history study revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week, with 34% of those bleeds requiring medical treatment. These bleeding episodes significantly impact patients’ mental health and quality of life, with 67% reporting low mood, 52% reporting emotional problems, and 46% experiencing social isolation. Additionally, 81% of participants reported missing school or work due to bruising or bleeding. To date, there are no effective prophylactic treatment options for GT.

About sutacimig (formerly HMB-001)
Sutacimig is a subcutaneously administered bispecific antibody that binds and stabilises endogenous Factor VIIa with one antibody arm and binds to TLT-1 on activated platelets with the other arm. This mechanism allows for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it facilitates haemostatic plug formation. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration granted Fast Track Designation and Orphan Drug Designation to sutacimig for the treatment of GT while the UK Medicines and Healthcare products Regulatory Agency has awarded it designation under the Innovative Licensing and Access Pathway (ILAP). For more information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterised by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening haemorrhages. Chronic blood loss frequently leads to iron deficiency anaemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying defect in VWF production or function.

About HMB-002
HMB-002 is a monovalent human antibody developed as the first-in-class prophylactic treatment for VWD targeting the underlying root cause of the disease, a condition driven by a deficiency or defect in VWF, a key regulator of haemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852).

About Hemab Therapeutics
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5TM, targets building a pipeline of development programs to deliver long-awaited innovation for people with high unmet need diseases like Glanzmann thrombasthenia, Factor VII Deficiency, Von Willebrand Disease, and others. Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.